Key result
Formulary Monograph Service outlines May 2009 reviews with no comparative clinical outcome data.
Key points are not available for this paper at this time.
Design
Other
Answers are grounded in this paper and cite their sources.
No data or results provided; leaves open any evaluation of the listed monograph topics.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 2009 monograph topics are febuxostat, antithrombin (recombinant), calcitriol ointment, trabectedin, and tesamorelin. The class review is on drugs used in the therapy of benign prostatic hyperplasia, and the DUE is on febuxostat.
No takes yet. Share an insight, caveat, or question.
Cada et al. (2009) studied this question. This abstract describes The Formulary Monograph Service and lists its May 2009 monograph topics, providing no clinical trial data or quantitative results.
Synapse has enriched 10 related papers. Consider them for comparative context: